How should we best target the biology of ER PR HER2 negative breast cancer?
A.N.J. Tutt, J.S. Reis-FilhoVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70703-1
File:
PDF, 55 KB
english, 2008